Impact of Macrophage Migration Inhibitory Factor Gene Polymorphisms and Serum Macrophage Migration Inhibitory Factor Levels on Pulmonary and Spinal Tuberculosis Susceptibility: A Pooled Analysis.

This study was designed to evaluate the association between macrophage migration inhibitory factor () gene polymorphisms, serum MIF levels and tuberculosis (TB) susceptibility. All satisfactory studies were included; the genotype number and serum MIF levels were reviewed. The Stata and Review Manager software were used for the pooled analyses. The pooled analyses showed that the -173G/C gene polymorphism was associated with TB (allele C vs allele G: odds ratio (OR) = 1.44, 95% confidence interval (CI): 1.28-1.62,  < 0.01; genotype CC vs genotype GG: OR = 1.69, 95% CI: 1.05-2.73,  = 0.03; genotype CC+GC vs genotype GG: OR = 1.56, 95% CI: 1.34-1.81,  < 0.01; genotype GC vs genotype GG: OR = 1.50, 95% CI: 1.28-1.75,  < 0.01). The subgroup analysis showed that the -173G/C gene polymorphism was significantly associated with the risk of both pulmonary tuberculosis (PTB) and spinal tuberculosis (STB).The CATT-794 gene polymorphism was associated with the PTB susceptibility in Asian subjects (genotypes 5/X+6/X vs genotypes 7/X+8/X: OR = 0.39, 95% CI: 0.24-0.64,  < 0.01; genotypes 5 + 6 vs genotypes 7 + 8: OR = 0.57, 95% CI: 0.48-0.69,  < 0.01). Both PTB and STB patients had significantly elevated serum MIF levels compared to healthy controls. The -173G/C gene polymorphism is related to both PTB and STB susceptibility in both Asian and Caucasian populations. The C allele and CC genotype of the -173G/C SNP appear to be TB risk factors. The CATT-794 gene polymorphism is associated with the PTB susceptibility in Asian subjects; serum MIF levels were significantly increased in PTB and STB patients.